
IDEAYA Biosciences, Inc. – NASDAQ:IDYA
IDEAYA Biosciences stock price today
IDEAYA Biosciences stock price monthly change
IDEAYA Biosciences stock price quarterly change
IDEAYA Biosciences stock price yearly change
IDEAYA Biosciences key metrics
Market Cap | 2.18B |
Enterprise value | 499.32M |
P/E | -8.79 |
EV/Sales | 9.80 |
EV/EBITDA | -9.11 |
Price/Sales | 11.08 |
Price/Book | 1.61 |
PEG ratio | 12.39 |
EPS | -2.01 |
Revenue | N/A |
EBITDA | -158.14M |
Income | -128.89M |
Revenue Q/Q | -100% |
Revenue Y/Y | -67.32% |
Profit margin | -119.27% |
Oper. margin | -122.72% |
Gross margin | 0% |
EBIT margin | -122.72% |
EBITDA margin | N/A |
create your own Smart Feed
Personalize your watchlist with companies you want to keep track of and get notified in the smart feed every time fresh news arrives.
Sign up for freeIDEAYA Biosciences stock price history
IDEAYA Biosciences stock forecast
IDEAYA Biosciences financial statements
$54.11
Potential upside: 129.47%
Analysts Price target
Financials & Ratios estimates
Jun 2023 | 3.54M | -27.92M | -787.98% |
---|---|---|---|
Sep 2023 | 8.03M | -27.44M | -341.38% |
Dec 2023 | 3.92M | -33.95M | -865.54% |
Mar 2024 | 0 | -39.57M |
Jun 2023 | 527557000 | 527.55M | 100% |
---|---|---|---|
Sep 2023 | 532942000 | 24.89M | 4.67% |
Dec 2023 | 649316000 | 28.22M | 4.35% |
Mar 2024 | 961527000 | 26.21M | 2.73% |
Jun 2023 | -33.46M | -121.38M | 191.06M |
---|---|---|---|
Sep 2023 | -30.17M | 51.34M | 27.83M |
Dec 2023 | -23.74M | -111.94M | 140.89M |
Mar 2024 | -43.81M | -353.97M | 349.11M |
IDEAYA Biosciences alternative data
Sep 2023 | 116 |
---|---|
Oct 2023 | 116 |
Nov 2023 | 116 |
Dec 2023 | 122 |
Jan 2024 | 122 |
Feb 2024 | 122 |
Mar 2024 | 124 |
Apr 2024 | 124 |
May 2024 | 124 |
Jun 2024 | 124 |
Jul 2024 | 124 |
IDEAYA Biosciences other data
Period | Buy | Sel |
---|---|---|
Jul 2023 | 0 | 9485 |
Aug 2023 | 0 | 17500 |
Sep 2023 | 0 | 6837 |
Nov 2023 | 0 | 5163 |
Dec 2023 | 0 | 87000 |
Jan 2024 | 0 | 79000 |
Feb 2024 | 0 | 102000 |
May 2024 | 0 | 203500 |
Transaction | Date | Insider | Security | Shares | Price per share | Total value | Source |
---|---|---|---|---|---|---|---|
Option | THRONE JASON officer: Chief Le.. | Common Stock | 47,060 | $7.01 | $329,891 | ||
Option | THRONE JASON officer: Chief Le.. | Stock Option (Right to Buy) | 6,424 | $13.34 | $85,696 | ||
Option | THRONE JASON officer: Chief Le.. | Common Stock | 6,424 | $13.34 | $85,696 | ||
Option | THRONE JASON officer: Chief Le.. | Stock Option (Right to Buy) | 47,060 | $7.01 | $329,891 | ||
Option | WHITE MICHAEL ANTHONY officer: Chief Scientific Officer | Stock Option (right to buy) | 28,500 | $12.86 | $366,510 | ||
Option | WHITE MICHAEL ANTHONY officer: Chief Scientific Officer | Common Stock | 28,500 | $12.86 | $366,510 | ||
Sale | WHITE MICHAEL ANTHONY officer: Chief Scientific Officer | Common Stock | 27,649 | $36.23 | $1,001,585 | ||
Sale | WHITE MICHAEL ANTHONY officer: Chief Scientific Officer | Common Stock | 851 | $36.78 | $31,296 | ||
Option | HATA YUJIRO S director, officer.. | Common Stock | 34,433 | $4.31 | $148,406 | ||
Sale | HATA YUJIRO S director, officer.. | Common Stock | 30,084 | $41.73 | $1,255,496 |
Patent |
---|
Application Filling date: 25 Sep 2018 Issue date: 21 Jul 2022 |
Application Filling date: 9 Dec 2019 Issue date: 7 Apr 2022 |
Application Filling date: 29 Jan 2020 Issue date: 31 Mar 2022 |
Application Filling date: 30 Jan 2020 Issue date: 16 Dec 2021 |
Application Filling date: 17 Jun 2019 Issue date: 2 Dec 2021 |
Grant Filling date: 12 Feb 2021 Issue date: 28 Sep 2021 |
Application METHODS OF CULTURING AND/OR EXPANDING STEM CELLS AND/OR LINEAGE COMMITTED PROGENITOR CELLS USING LACTAM COMPOUNDS Filling date: 5 Jun 2019 Issue date: 19 Aug 2021 |
Grant Filling date: 12 Feb 2021 Issue date: 10 Aug 2021 |
Grant Filling date: 12 Feb 2021 Issue date: 29 Jun 2021 |
Application Filling date: 18 Jul 2018 Issue date: 22 Apr 2021 |
Quarter | Transcript |
---|---|
Q4 2021 15 Mar 2022 | Q4 2021 Earnings Call Transcript |
Delcath Systems: Growing Fast, But Business Model Is Fragile
Ideaya Biosciences: Value Beyond Darovasertib With ADC Program IDE849
Ideaya Biosciences: These Prices Are Probably Going To Look Cheap Sooner Than Later
Adoption Of Delcath's Hepzato Kit Will Snowball Quicker Than The Market Expects
IDEAYA's Triple Threat: Melanoma, Money, And Momentum
Ideaya Biosciences: Eye Cancer Therapy Drives Gains - More Upside Ahead
Ideaya Biosciences Has A Strong Pipeline And Looks Investible
Ideaya Biosciences: Prospects Rebound With Updated Uveal Melanoma Data
Repare Therapeutics: Budding Synthetic Lethality Player With 3 Big Pharma Partners
-
What's the price of IDEAYA Biosciences stock today?
One share of IDEAYA Biosciences stock can currently be purchased for approximately $23.58.
-
When is IDEAYA Biosciences's next earnings date?
Unfortunately, IDEAYA Biosciences's (IDYA) next earnings date is currently unknown.
-
Does IDEAYA Biosciences pay dividends?
No, IDEAYA Biosciences does not pay dividends.
-
How much money does IDEAYA Biosciences make?
IDEAYA Biosciences has a market capitalization of 2.18B and it's past years’ income statements indicate that its last revenue has decreased compared to the previous period by 54.08% to 23.39M US dollars.
-
What is IDEAYA Biosciences's stock symbol?
IDEAYA Biosciences, Inc. is traded on the NASDAQ under the ticker symbol "IDYA".
-
What is IDEAYA Biosciences's primary industry?
Company operates in the Healthcare sector and Biotechnology industry.
-
How do i buy shares of IDEAYA Biosciences?
Shares of IDEAYA Biosciences can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
-
Who are IDEAYA Biosciences's key executives?
IDEAYA Biosciences's management team includes the following people:
- Mr. Yujiro S. Hata Co-Founder, Chief Executive Officer, Pres & Director(age: 51, pay: $711,330)
- Mr. Paul A. Stone Senior Vice President, Chief Financial Officer & Principal Accounting Officer(age: 61, pay: $508,440)
- Mr. Jason S. Throne J.D., Esq. Senior Vice President, Gen. Counsel & Company Sec.(age: 53, pay: $425,560)
-
Is IDEAYA Biosciences founder-led company?
Yes, IDEAYA Biosciences is a company led by its founder Mr. Yujiro S. Hata.
-
How many employees does IDEAYA Biosciences have?
As Jul 2024, IDEAYA Biosciences employs 124 workers.
-
When IDEAYA Biosciences went public?
IDEAYA Biosciences, Inc. is publicly traded company for more then 6 years since IPO on 23 May 2019.
-
What is IDEAYA Biosciences's official website?
The official website for IDEAYA Biosciences is ideayabio.com.
-
Where are IDEAYA Biosciences's headquarters?
IDEAYA Biosciences is headquartered at 7000 Shoreline Court, South San Francisco, CA.
-
How can i contact IDEAYA Biosciences?
IDEAYA Biosciences's mailing address is 7000 Shoreline Court, South San Francisco, CA and company can be reached via phone at +65 04436209.
-
What is IDEAYA Biosciences stock forecast & price target?
Based on 8 Wall Street analysts` predicted price targets for IDEAYA Biosciences in the last 12 months, the avarage price target is $54.11. The average price target represents a 129.47% change from the last price of $23.58.
IDEAYA Biosciences company profile:

IDEAYA Biosciences, Inc.
ideayabio.comNASDAQ
124
Biotechnology
Healthcare
IDEAYA Biosciences, Inc., a synthetic lethality-focused precision medicine oncology company, focuses on the discovery and development of targeted therapeutics for patient populations selected using molecular diagnostics. The company's lead product candidates include IDE397, a methionine adenosyltransferase 2a inhibitor that is in Phase I clinical trial for patients with solid tumors having methylthioadenosine phosphorylase deletions; and IDE196, a protein kinase C inhibitor that is in Phase I/II clinical trial for genetically defined cancers having GNAQ or GNA11 gene mutations. Its preclinical pipeline includes various synthetic lethality programs targeting PARG inhibitor in tumors for patients having tumors with a defined biomarker based on genetic mutations and/or molecular signatures; Pol Theta inhibitors in tumors with BRCA or other homologous recombination deficiency mutations; and WRN inhibitors in tumors with high microsatellite instability. The company has a research collaboration agreement with Cancer Research UK and the University of Manchester to develop small molecule inhibitors of Poly (ADP-ribose) glycohydrolase; and a clinical trial collaboration and supply agreement with Pfizer Inc. for Phase I/II study in metastatic uveal melanoma, skin melanoma, and other solid tumors, as well as a strategic partnership with GlaxoSmithKline plc. IDEAYA Biosciences, Inc. was incorporated in 2015 and is headquartered in South San Francisco, California.
South San Francisco, CA 94080
CIK: 0001676725
ISIN: US45166A1025
CUSIP: 45166A102